药物治疗心衰并慢性肾脏病患者的疗效及安全性2018幻灯片资料.pptxVIP

European Heart Journal (2013)34, 2453–2463新型盐皮质受体拮抗剂治疗心衰并慢性肾脏病患者的疗效及安全性2013LOGOMethods and resultsThis randomized, controlled, phase II trial consisted of two parts. In part A, the safety and tolerability of oral BAY 94-8862[2.5, 5, or 10 mg once daily (q.d.)] was assessed in 65 patients with HFrEF and mild CKD. In part B, BAY 94-8862 (2.5, 5, or 10 mg q.d., or 5 mg twice daily) was compared with placebo and open-label spironolactone (25 or 50 mg/day) in 392 patients with HFrEF and moderate CKD.LOGOResultsBAY 94-8862 was associated with significantly smaller mean increases in serum potassium c